RIPPEDTIDE BIOLABS
DRIVEN BY RESEARCH. BUILT FOR TRANSFORMATION.

SS-31 / ELAMIPRETIDE

MITOCHONDRIAL MEDICINE—APPROVAL IS NARROW

Benefits, research claims, evidence boundaries, and safety context—in one page.

MITOCHONDRIAL TARGET

LIMITED FDA APPROVAL

WHAT THE EVIDENCE IS STUDYING

Elamipretide (historically studied as SS-31) is a mitochondria-targeting tetrapeptide. Its approved use is narrow and should not be generalized to performance, aging, or wellness claims.

RESEARCH PROFILE

- **Brand**
  Forzinity
- **Approved population**
  Barth syndrome ≥30 kg
- **Approval basis**
  Accelerated approval

EVIDENCE REALITY CHECK

In September 2025, FDA granted accelerated approval to Forzinity to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. Broader mitochondrial claims remain investigational.

BEST WAY TO DESCRIBE IT

An approved orphan-disease medicine—not a general mitochondrial enhancer.

SCAN FOR THE LIVE GUIDE

Opens the current printable PDF at rippedtidebiolabs.com.

Permanent Education Center resource link.

1 BARTH SYNDROME

Forzinity is approved for a rare genetic mitochondrial disorder in a defined weight group. Continued approval may depend on confirmation of clinical benefit.

2 CARDIOLIPIN BIOLOGY

Elamipretide associates with cardiolipin-rich inner mitochondrial membranes and is studied for effects on mitochondrial structure and energetics.

3 BROADER RESEARCH

Studies in heart, muscle, kidney, eye, and age-related conditions have produced a mixed evidence base. They do not create a general wellness indication.

4 PRODUCT IDENTITY

The FDA-approved drug has controlled manufacturing and labeling. Products sold as research SS-31 or compounded elamipretide are not automatically equivalent.

IMPORTANT SAFETY + REGULATORY NOTE

Use for the approved indication requires prescription oversight and label-based monitoring. Injection-site reactions are important. Safety and effectiveness for bodybuilding, recovery, anti-aging, fatigue, or general mitochondrial support are not established. Do not extrapolate dosing or purity from Forzinity to non-approved products.

Sources: FDA, Forzinity (elamipretide) accelerated approval announcement, Sep. 19, 2025; FDA Drug Trials Snapshot: Forzinity; current Prescribing Information.